Artículos por temáticas
En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.
FILTRAR POR:
Tema
Tratamiento no farmacológico
364 ARTíCULOS , VIENDO DEL 316 AL 330
Overlapped metabolic and therapeutic links between Alzheimer and diabetes
Ahmad W.
Mol Neurobiol. 2013 Feb;47(1):399-424. doi: 10.1007/s12035-012-8352-z. Epub 2012 Sep 26.
0
0
0
Intravenous immunoglobulin and Alzheimer's disease: what now?
Loeffler DA.
J Neuroinflammation. 2013 Jun 5;10:70. doi: 10.1186/1742-2094-10-70.
0
0
0
Noetzli M, Eap CB.
Clin Pharmacokinet. 2013 Apr;52(4):225-41. doi: 10.1007/s40262-013-0038-9.
0
0
0
Non-pharmacological interventions and neuroplasticity in early stage Alzheimer's disease
Herholz SC, Herholz RS, Herholz K.
Expert Rev Neurother. 2013 Nov;13(11):1235-45. doi: 10.1586/14737175.2013.845086. Epub 2013 Oct 17.
0
0
0
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease
Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, Errico F, Mercuri NB, Nicoletti F, Nisticò R.
Drug Des Devel Ther. 2013 Nov 13;7:1359-64. doi: 10.2147/DDDT.S53401. eCollection 2013.
0
0
0
Drug development status for Alzheimer's disease: present scenario
Misra S, Medhi B.
Neurol Sci. 2013 Jun;34(6):831-9. doi: 10.1007/s10072-013-1316-x. Epub 2013 Feb 8.
0
0
0
Acute dystonic reaction with rivastigmine
Dhikav V, Anand KS.
Int Psychogeriatr. 2013 Aug;25(8):1385-6. doi: 10.1017/S104161021300029X. Epub 2013 Apr 8.
0
0
0
Pierce A.
Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):519-37. doi: 10.1212/01.CON.0000429166.97320.81.
0
0
0
An evidence-based systematic review on cognitive interventions for individuals with dementia
Hopper T, Bourgeois M, Pimentel J, Qualls CD, Hickey E, Frymark T, Schooling T.
Am J Speech Lang Pathol. 2013 Feb;22(1):126-45. doi: 10.1044/1058-0360(2012/11-0137). Epub 2012 Jul 30.
0
0
0
Cholinesterase inhibitors in vascular cognitive impairment
Massoud F.
Can J Neurol Sci. 2013 Jul;40(4):446-7. doi: 10.1017/s0317167100014487.
0
0
0
Nutritional approaches in the risk reduction and management of Alzheimer's disease
Mi W, van Wijk N, Cansev M, Sijben JW, Kamphuis PJ.
Nutrition. 2013 Sep;29(9):1080-9. doi: 10.1016/j.nut.2013.01.024. Epub 2013 Jun 4.
0
0
0
Autophagy modulation for Alzheimer's disease therapy
Zhu XC, Yu JT, Jiang T, Tan L.
Mol Neurobiol. 2013 Dec;48(3):702-14. doi: 10.1007/s12035-013-8457-z. Epub 2013 Apr 27.
0
0
0
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease
Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, Abushakra S, Hartley DM, Petersen RC, Khachaturian AS, Sperling RA.
Alzheimers Dement. 2013 Mar;9(2):123-131.e1. doi: 10.1016/j.jalz.2012.12.004. Epub 2013 Feb 12.
0
0
0
A 10-year perspective on donepezil
Cheewakriengkrai L, Gauthier S.
Expert Opin Pharmacother. 2013 Feb;14(3):331-8. doi: 10.1517/14656566.2013.760543. Epub 2013 Jan 14.
0
0
0
New and different approaches needed for the design and execution of Alzheimer's clinical trials
Carrillo MC, Vellas B.
Alzheimers Dement. 2013 Jul;9(4):436-7. doi: 10.1016/j.jalz.2013.03.008.
0
0
0
Comentarios
En ningún caso la información facilitada constituye asesoramiento por parte de Zambon
Con el aval de:
En colaboración con:
